Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $146.00

Kymera Therapeutics (NASDAQ:KYMR) had its target price increased by Morgan Stanley from $135.00 to $146.00 in a report published on Tuesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other analysts have also recently weighed in on the company. Bank of America lifted their price target on Kymera Therapeutics from $123.00 to $144.00 and gave the stock a “buy” rating in a report on Monday, September 14th. Citigroup upped their price objective on Kymera Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a report on Monday, October 5th. Wells Fargo & Company increased their price objective on Kymera Therapeutics from $116.00 to $151.00 and gave the stock an “overweight” rating in a research report on Thursday, August 27th. Raymond James Financial initiated coverage on Kymera Therapeutics in a report on Thursday, October 8th. They set an “outperform” rating and a $140.00 target price for the company. Finally, Wolfe Research raised Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $180.00 target price for the company in a report on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $137.32.

Kymera Therapeutics Trading Up 0.1%

Shares of KYMR opened at $122.60 on Tuesday. The company has a market cap of $10.19 billion, a price-to-earnings ratio of -37.84 and a beta of 1.98. Kymera Therapeutics has a 1-year low of $55.66 and a 1-year high of $130.05. The company’s fifty day simple moving average is $114.83 and its 200 day simple moving average is $96.08.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, October 29th. The company reported ($1.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.26) by ($0.06). Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The business had revenue of $1.35 million during the quarter, compared to the consensus estimate of $3.28 million. During the same quarter in the prior year, the company earned ($0.94) EPS. Kymera Therapeutics’s quarterly revenue was up .0% on a year-over-year basis. As a group, research analysts forecast that Kymera Therapeutics will post -3.85 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Brian Adams sold 6,371 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $116.83, for a total transaction of $744,323.93. Following the sale, the insider directly owned 50,254 shares in the company, valued at approximately $5,871,174.82. The trade was a 11.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $113.80, for a total transaction of $3,414,000.00. Following the sale, the chief executive officer directly owned 666,568 shares in the company, valued at $75,855,438.40. The trade was a 4.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 15.98% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

A number of hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Kymera Therapeutics during the second quarter valued at $635,067,000. Merck & Co. Inc. acquired a new stake in Kymera Therapeutics during the 2nd quarter worth about $88,544,161. Bank of America Corp DE bought a new position in shares of Kymera Therapeutics in the 2nd quarter worth about $43,378,000. Braidwell LP raised its position in shares of Kymera Therapeutics by 12.0% in the 2nd quarter. Braidwell LP now owns 378,163 shares of the company’s stock worth $43,364,000 after acquiring an additional 40,604 shares in the last quarter. Finally, Jennison Associates LLC raised its position in shares of Kymera Therapeutics by 2.5% in the 1st quarter. Jennison Associates LLC now owns 508,999 shares of the company’s stock worth $42,395,000 after acquiring an additional 12,334 shares in the last quarter.

Trending Headlines about Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: KT-579 produced encouraging Phase 1 results. Kymera reported deep and sustained IRF5 degradation, strong changes in disease-relevant biomarkers and a favorable safety profile in healthy volunteers. The data support continued development of KT-579 for immunological diseases and were the most important positive catalyst in the update. Kymera Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
• Positive Sentiment: BTIG Research raised its price target to $139 from $134 and maintained a Buy rating. The revised target implies approximately 13.4% potential upside based on the referenced share price, signaling continued analyst confidence in Kymera’s pipeline and outlook. BTIG Research Kymera Ratings
• Neutral Sentiment: Management’s Q3 earnings call focused on the KT-579 results and broader pipeline progress. Investors are likely looking for additional details on development plans, upcoming milestones and the company’s financial resources; the available transcript listings do not provide further quantified guidance. Kymera Q3 2026 Earnings Call Transcript
• Negative Sentiment: Quarterly results were weaker than expected. Kymera reported a third-quarter loss of $1.32 per share versus the $1.26 consensus estimate, while the year-ago loss was $0.94 per share. Revenue was essentially unchanged year over year, and the company continued to report a deeply negative net margin, underscoring its ongoing reliance on clinical development funding. Kymera Reports Third Quarter and Nine-Month Earnings Results

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing medicines that selectively eliminate disease-causing proteins through targeted protein degradation. Its approach is designed to use the cell’s natural protein-disposal system to remove proteins that may be difficult to address with conventional drug modalities.

The company’s research and development programs have targeted a range of disease areas, including immune-mediated and inflammatory conditions, cancer, and other serious illnesses.